This company has been marked as potentially delisted and may not be actively trading. iTeos Therapeutics (ITOS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for ITOS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for iTeos Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITOS Analyst Ratings Over TimeTypeCurrent Forecast10/20/24 to 10/20/251 Month Ago9/20/24 to 9/20/253 Months Ago7/22/24 to 7/22/251 Year Ago10/21/23 to 10/20/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)4 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)6 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$15.50$15.50$15.64$30.50Forecasted Upside52.71% Upside52.71% Upside54.57% Upside223.44% UpsideConsensus RatingHoldHoldHoldBuy ITOS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ITOS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table iTeos Therapeutics Stock vs. The CompetitionTypeiTeos TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.14 2.33 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside52.71% Upside1,357.67% Upside13.61% UpsideNews Sentiment RatingNeutral NewsSee Recent ITOS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails8/7/2025Wells Fargo & Company3 of 5 starsEva Fortea Not RatedLower TargetEqual Weight$12.00 ➝ $11.00+8.64%7/21/2025Piper Sandler2 of 5 stars DowngradeStrong-Buy ➝ Hold7/21/2025Wedbush4 of 5 stars Reiterated RatingOutperform$12.00 ➝ $10.50+3.65%5/14/2025Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingChristopher RaymondSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$12.00+59.62%5/14/2025Leerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingD. GrayboschSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSwayampakula RamakanthSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDaina GrayboschSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.00+14.65%5/13/2025JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian ChengSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.00-0.25%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:04 AM ET. ITOS Forecast - Frequently Asked Questions What is iTeos Therapeutics' forecast for 2025? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for iTeos Therapeutics is $15.50, with a high forecast of $46.00 and a low forecast of $8.00. Should I buy or sell iTeos Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ITOS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITOS, but not buy additional shares or sell existing shares. Does iTeos Therapeutics's stock price have much upside? According to analysts, iTeos Therapeutics's stock has a predicted upside of 52.71% based on their 12-month stock forecasts. What analysts cover iTeos Therapeutics? iTeos Therapeutics has been rated by research analysts at Wells Fargo & Company in the past 90 days. Do Wall Street analysts like iTeos Therapeutics more than its competitors? Analysts like iTeos Therapeutics less than other "medical" companies. The consensus rating score for iTeos Therapeutics is 2.14 while the average consensus rating score for "medical" companies is 2.33. Learn more on how ITOS compares to other companies. Stock Forecasts and Research Tools Related Companies Structure Therapeutics Stock Forecast Biohaven Stock Forecast Stoke Therapeutics Stock Forecast AbCellera Biologics Stock Forecast Immunocore Stock Forecast Vericel Stock Forecast Janux Therapeutics Stock Forecast Edgewise Therapeutics Stock Forecast Arcus Biosciences Stock Forecast Harmony Biosciences Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ITOS) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
